In patients with pancreatic ductal adenocarcinoma, KRAS G12D and G12V mutations hare associated with worse patient outcomes, ...
Ever Evaluation of SIL-204 in Clinically Relevant Orthotopic Models; Analysis Underway with Initial Results Expected in ...
Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically ...
Alice Rees initially put the pain under her ribs and nausea that she experienced while on holiday with friends in July 2023 ...
Clinical studies indicate that the mRNA vaccine may help treat pancreatic cancer, one of the deadliest cancers, reports ...
Cardiff Oncology (NASDAQ:CRDF – Get Free Report) will likely be announcing its earnings results before the market opens on ...
Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK ...
On Jan. 2, Hookipa inked a non-binding agreement that would have created a merged company with Poolbeg via an all-stock ...
This recognition follows another recent honor for Mr. Kras, who was named a finalist for the Entrepreneur Of The Year® 2024 New Jersey Award by Ernst & Young (EY US). This award celebrates innovative ...
Medical experts discuss strategies for managing adverse events associated with KRAS-targeted therapies, addressing monitoring ...
Groups partner on research project to test innovative new treatment for KRAS-mutant cancer being developed at Hebrew ...
Cardiff Oncology's Onvansertib shows promise in treating RAS-mutated cancers, especially mCRC. See why I rate CRDF stock as a ...